{
    "abstract": "Background: To support vaccination programs in developing countries, a 4-dose vial presentation of pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was developed. This study assessed immunologic non-inferiority and safety of the investigational PHiD-CV 4-dose versus licensed 1-dose vial presentation in infants. Methods: In this phase III, mono-center, observer-blind study in Bangladesh, 6\u201310-week-old infants were randomized 1:1 to receive PHiD-CV primary vaccination (at ages 6, 10, 18 weeks) and a booster dose (at age 9 months) with a 4-dose vial (with preservative, 4DV group) or 1-dose vial (preservative-free, 1DV group). DTPw-HBV/Hib was (co)-administered per study protocol and polio, measles and rubella vaccines as part of the national immunization program. Non-inferiority of PHiD-CV 4-dose versus 1-dose vial for each vaccine pneumococcal serotype (VT) and vaccine-related serotype 19A in terms of antibody geometric mean concentration (GMC) was assessed (criterion: upper limit of 2-sided 95% confidence interval of antibody GMC ratios [1DV/4DV] <2-fold). Immune responses were measured. Solicited, unsolicited and serious adverse events (AEs) were evaluated. Results: Of 320 infants (160 per group) vaccinated during the primary vaccination phase, 297 received a booster. Non-inferiority was demonstrated for each VT and 19A. One month post-primary vaccination, for most VT, \u226597.9% of infants in each group had antibody concentrations \u22650.2 \u03bcg/mL; for 19A \u2265 80.1% reached this threshold. Pneumococcal antibody responses and opsonophagocytic activity for each VT and 19A were within similar ranges between groups after primary and booster vaccination, as were anti-protein D responses. Booster immune responses were observed in both groups. Reported AEs were within similar ranges for both presentations. Conclusion: Immunologic non-inferiority of PHiD-CV 4-dose vial (with preservative) versus PHiD-CV 1-dose vial (preservative-free) was demonstrated. Immune responses and reactogenicity following primary/booster vaccination were within similar ranges for both presentations. PHiD-CV 4-dose vial would help improve access and coverage in resource-limited countries. Clinical Trial Registry: NCT02447432.",
    "bib_entries": {
        "b0005": {
            "authors": [],
            "firstpage": "129",
            "issn": "00498114",
            "lastpage": "144",
            "pmid": "24340399",
            "pub_year": 2012,
            "title": "Pneumococcal vaccines WHO position paper--2012.",
            "volume": "87"
        },
        "b0010": null,
        "b0015": null,
        "b0020": {
            "authors": [
                {
                    "first": "Arto A.",
                    "initial": "A.A.",
                    "last": "Palmu"
                },
                {
                    "first": "Jukka",
                    "initial": "J.",
                    "last": "Jokinen"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "Heta",
                    "initial": "H.",
                    "last": "Nieminen"
                },
                {
                    "first": "Esa",
                    "initial": "E.",
                    "last": "Ruokokoski"
                },
                {
                    "first": "Lotta",
                    "initial": "L.",
                    "last": "Siira"
                },
                {
                    "first": "Taneli",
                    "initial": "T.",
                    "last": "Puumalainen"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Lommel"
                },
                {
                    "first": "Marjan",
                    "initial": "M.",
                    "last": "Hezareh"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Moreira"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                },
                {
                    "first": "Terhi M.",
                    "initial": "T.M.",
                    "last": "Kilpi"
                }
            ],
            "doi": "10.1016/S0140-6736(12)61854-6",
            "firstpage": "214",
            "issn": "01406736",
            "lastpage": "222",
            "pub_year": 2013,
            "title": "Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: A cluster randomised trial",
            "volume": "381"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Miguel W.",
                    "initial": "M.W.",
                    "last": "Tregnaghi"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "S\u00e1ez-Llorens"
                },
                {
                    "first": "Pio",
                    "initial": "P.",
                    "last": "L\u00f3pez"
                },
                {
                    "first": "Hector",
                    "initial": "H.",
                    "last": "Abate"
                },
                {
                    "first": "Enrique",
                    "initial": "E.",
                    "last": "Smith"
                },
                {
                    "first": "Adriana",
                    "initial": "A.",
                    "last": "P\u00f3sleman"
                },
                {
                    "first": "Arlene",
                    "initial": "A.",
                    "last": "Calvo"
                },
                {
                    "first": "Digna",
                    "initial": "D.",
                    "last": "Wong"
                },
                {
                    "first": "Carlos",
                    "initial": "C.",
                    "last": "Cortes-Barbosa"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "Ceballos"
                },
                {
                    "first": "Marcelo",
                    "initial": "M.",
                    "last": "Tregnaghi"
                },
                {
                    "first": "Alexandra",
                    "initial": "A.",
                    "last": "Sierra"
                },
                {
                    "first": "Mirna",
                    "initial": "M.",
                    "last": "Rodriguez"
                },
                {
                    "first": "Marisol",
                    "initial": "M.",
                    "last": "Troiti\u00f1o"
                },
                {
                    "first": "Carlos",
                    "initial": "C.",
                    "last": "Carabajal"
                },
                {
                    "first": "Andrea",
                    "initial": "A.",
                    "last": "Falaschi"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "Leandro"
                },
                {
                    "first": "Maria Mercedes",
                    "initial": "M.M.",
                    "last": "Castrej\u00f3n"
                },
                {
                    "first": "Alejandro",
                    "initial": "A.",
                    "last": "Lepetic"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Lommel"
                },
                {
                    "first": "William P.",
                    "initial": "W.P.",
                    "last": "Hausdorff"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "Javier Ruiz",
                    "initial": "J.R.",
                    "last": "Gui\u00f1az\u00fa"
                },
                {
                    "first": "Eduardo",
                    "initial": "E.",
                    "last": "Ortega-Barr\u00eda"
                },
                {
                    "first": "Juan P.",
                    "initial": "J.P.",
                    "last": "Yarz\u00e1bal"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1371/journal.pmed.1001657",
            "firstpage": "1",
            "issn": "15491277",
            "lastpage": "18",
            "pmid": "24892763",
            "pub_year": 2014,
            "title": "Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial",
            "volume": "11"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "De Wals"
                },
                {
                    "first": "Genevi\u00e8ve",
                    "initial": "G.",
                    "last": "Deceuninck"
                },
                {
                    "first": "Gaston",
                    "initial": "G.",
                    "last": "De Serres"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.06.104",
            "firstpage": "2053",
            "issn": "0264410X",
            "lastpage": "2054",
            "pmid": "27021043",
            "pub_year": 2016,
            "title": "Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada",
            "volume": "34"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Genevi\u00e8ve",
                    "initial": "G.",
                    "last": "Deceuninck"
                },
                {
                    "first": "Gaston",
                    "initial": "G.",
                    "last": "De Serres"
                },
                {
                    "first": "Nicole",
                    "initial": "N.",
                    "last": "Boulianne"
                },
                {
                    "first": "Brigitte",
                    "initial": "B.",
                    "last": "Lefebvre"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "De Wals"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.04.005",
            "firstpage": "2684",
            "issn": "0264410X",
            "lastpage": "2689",
            "pmid": "25887086",
            "pub_year": 2015,
            "title": "Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada",
            "volume": "33"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Carla Magda Allan S.",
                    "initial": "C.M.A.S.",
                    "last": "Domingues"
                },
                {
                    "first": "Jennifer R.",
                    "initial": "J.R.",
                    "last": "Verani"
                },
                {
                    "first": "Ernesto Issac",
                    "initial": "E.I.",
                    "last": "Montenegro Renoiner"
                },
                {
                    "first": "Maria Cristina",
                    "initial": "M.C.",
                    "last": "de Cunto Brandileone"
                },
                {
                    "first": "Brendan",
                    "initial": "B.",
                    "last": "Flannery"
                },
                {
                    "first": "Lucia Helena",
                    "initial": "L.H.",
                    "last": "de Oliveira"
                },
                {
                    "first": "Jo\u00e3o Barberino",
                    "initial": "J.B.",
                    "last": "Santos"
                },
                {
                    "first": "Jos\u00e9 C\u00e1ssio",
                    "initial": "J.C.",
                    "last": "de Moraes"
                },
                {
                    "first": "Regina Coeli Magalh\u00e3es",
                    "initial": "R.C.M.",
                    "last": "Rodrigues"
                },
                {
                    "first": "Marluce Aparecida Assun\u00e7\u00e3o",
                    "initial": "M.A.A.",
                    "last": "Oliveira"
                },
                {
                    "first": "Tani Maria Schilling",
                    "initial": "T.M.S.",
                    "last": "Ranieri"
                },
                {
                    "first": "Gladys Maria",
                    "initial": "G.M.",
                    "last": "Zubaran"
                },
                {
                    "first": "Ana L\u00eddia Lima",
                    "initial": "A.L.L.",
                    "last": "Solon"
                },
                {
                    "first": "Maria Iracema",
                    "initial": "M.I.",
                    "last": "de Aguiar Patr\u00edcio"
                },
                {
                    "first": "Maria Elisa Paula",
                    "initial": "M.E.P.",
                    "last": "de Oliveira"
                },
                {
                    "first": "Rita",
                    "initial": "R.",
                    "last": "de C\u00e1ssia Vilasboas Silva"
                },
                {
                    "first": "Marlene Sera",
                    "initial": "M.S.",
                    "last": "Wille"
                },
                {
                    "first": "Pilar Gomes",
                    "initial": "P.G.",
                    "last": "Martinez"
                },
                {
                    "first": "Helena Keico",
                    "initial": "H.K.",
                    "last": "Sato"
                },
                {
                    "first": "Maria Cristina Hereny",
                    "initial": "M.C.H.",
                    "last": "Bordim"
                },
                {
                    "first": "Luzia Auxiliadora",
                    "initial": "L.A.",
                    "last": "Careli"
                },
                {
                    "first": "Vera L\u00facia",
                    "initial": "V.L.",
                    "last": "da Gl\u00f3ria Malheiros"
                },
                {
                    "first": "Zenize Rocha",
                    "initial": "Z.R.",
                    "last": "da Silva Costa"
                },
                {
                    "first": "Maria Goretti Varej\u00e3o",
                    "initial": "M.G.V.",
                    "last": "da Silva"
                },
                {
                    "first": "Cleidiane Santos",
                    "initial": "C.S.",
                    "last": "Rodrigues"
                },
                {
                    "first": "Ataiza C\u00e9sar",
                    "initial": "A.C.",
                    "last": "Vieira"
                },
                {
                    "first": "Lucila Tacac\u00f4",
                    "initial": "L.T.",
                    "last": "Watanabe"
                },
                {
                    "first": "Glaucia Gama Rahal",
                    "initial": "G.G.R.",
                    "last": "Aires"
                },
                {
                    "first": "Robmary Matias",
                    "initial": "R.M.",
                    "last": "de Almeida"
                },
                {
                    "first": "Diana Felicia",
                    "initial": "D.F.",
                    "last": "de Ara\u00fajo Margarido"
                },
                {
                    "first": "Ana L\u00facia Stone",
                    "initial": "A.L.S.",
                    "last": "de Souza"
                },
                {
                    "first": "Samanta C.G.",
                    "initial": "S.C.G.",
                    "last": "Almeida"
                },
                {
                    "first": "Angela P.",
                    "initial": "A.P.",
                    "last": "Brand\u00e3o"
                },
                {
                    "first": "Lincoln S.",
                    "initial": "L.S.",
                    "last": "Prado"
                },
                {
                    "first": "Maria Luiza L.S.",
                    "initial": "M.L.L.S.",
                    "last": "Guerra"
                },
                {
                    "first": "Orlando Cesar",
                    "initial": "O.C.",
                    "last": "Mantese"
                },
                {
                    "first": "Eitan",
                    "initial": "E.",
                    "last": "Berezin"
                },
                {
                    "first": "Cicero",
                    "initial": "C.",
                    "last": "Dias"
                },
                {
                    "first": "Cristiana",
                    "initial": "C.",
                    "last": "Nascimento"
                },
                {
                    "first": "Joice",
                    "initial": "J.",
                    "last": "Reis"
                },
                {
                    "first": "Ana Lucia",
                    "initial": "A.L.",
                    "last": "Andrade"
                },
                {
                    "first": "Solange",
                    "initial": "S.",
                    "last": "Andrade"
                },
                {
                    "first": "Flavia",
                    "initial": "F.",
                    "last": "Lobo"
                },
                {
                    "first": "Camile",
                    "initial": "C.",
                    "last": "de Moraes"
                },
                {
                    "first": "Eliane Castro",
                    "initial": "E.C.",
                    "last": "de Barros"
                },
                {
                    "first": "M\u00e1rcia Lopes",
                    "initial": "M.L.",
                    "last": "de Carvalho"
                },
                {
                    "first": "Elias Duarte Gon\u00e7alves",
                    "initial": "E.D.G.",
                    "last": "Correia"
                },
                {
                    "first": "Selma Lina",
                    "initial": "S.L.",
                    "last": "Suzuki"
                }
            ],
            "doi": "10.1016/S2213-2600(14)70060-8",
            "firstpage": "464",
            "issn": "22132600",
            "lastpage": "471",
            "pmid": "24726406",
            "pub_year": 2014,
            "title": "Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: A matched case-control study",
            "volume": "2"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Jennifer R.",
                    "initial": "J.R.",
                    "last": "Verani"
                },
                {
                    "first": "Carla Magda A.Santos",
                    "initial": "C.M.A.S.",
                    "last": "Domingues"
                },
                {
                    "first": "Jos\u00e9 Cassio de",
                    "initial": "J.C.d.",
                    "last": "Moraes"
                },
                {
                    "first": "Ernesto Renoiner",
                    "initial": "E.R.",
                    "last": "Montenegro"
                },
                {
                    "first": "Maria Cristina",
                    "initial": "M.C.",
                    "last": "de Cunto Brandileone"
                },
                {
                    "first": "Brendan",
                    "initial": "B.",
                    "last": "Flannery"
                },
                {
                    "first": "L\u00facia Helena",
                    "initial": "L.H.",
                    "last": "de Oliveira"
                },
                {
                    "first": "Jo\u00e3o Barberino",
                    "initial": "J.B.",
                    "last": "dos Santo Regina Coeli"
                },
                {
                    "first": "Magalh\u00e3es",
                    "initial": "M.",
                    "last": "Rodrigues"
                },
                {
                    "first": "Marluce Aparecida Assun\u00e7\u00e3o",
                    "initial": "M.A.A.",
                    "last": "Oliveira"
                },
                {
                    "first": "Tani Maria Schilling",
                    "initial": "T.M.S.",
                    "last": "Ranieri"
                },
                {
                    "first": "Gladys Maria",
                    "initial": "G.M.",
                    "last": "Zubaran"
                },
                {
                    "first": "Ana L\u00eddia Lima",
                    "initial": "A.L.L.",
                    "last": "Solon"
                },
                {
                    "first": "Maria Iracema",
                    "initial": "M.I.",
                    "last": "de Aguiar Patr\u00edcio"
                },
                {
                    "first": "Maria Elisa Paula",
                    "initial": "M.E.P.",
                    "last": "de Oliveira"
                },
                {
                    "first": "Rita",
                    "initial": "R.",
                    "last": "de C\u00e1ssia Vilasboas Silva"
                },
                {
                    "first": "Marlene Sera",
                    "initial": "M.S.",
                    "last": "Wille"
                },
                {
                    "first": "Pilar Gomes",
                    "initial": "P.G.",
                    "last": "Martinez"
                },
                {
                    "first": "Helena Keico",
                    "initial": "H.K.",
                    "last": "Sato"
                },
                {
                    "first": "Maria Cristina Hereny",
                    "initial": "M.C.H.",
                    "last": "Bordim"
                },
                {
                    "first": "Luzia Aux Iliadora",
                    "initial": "L.A.I.",
                    "last": "Careli"
                },
                {
                    "first": "Vera L\u00facia",
                    "initial": "V.L.",
                    "last": "da Gl\u00f3ria Malheiros"
                },
                {
                    "first": "Zenize Rocha",
                    "initial": "Z.R.",
                    "last": "da Silva Costa"
                },
                {
                    "first": "Maria Goretti Varej\u00e3o",
                    "initial": "M.G.V.",
                    "last": "da Silva"
                },
                {
                    "first": "Cleidiane Santos",
                    "initial": "C.S.",
                    "last": "Rodrigues"
                },
                {
                    "first": "Ataiza C\u00e9sar",
                    "initial": "A.C.",
                    "last": "Vieira"
                },
                {
                    "first": "Lucila Tacac\u00f4",
                    "initial": "L.T.",
                    "last": "Watanabe"
                },
                {
                    "first": "Glaucia Gama Rahal",
                    "initial": "G.G.R.",
                    "last": "Aires"
                },
                {
                    "first": "Robmary Matias",
                    "initial": "R.M.",
                    "last": "de Almeida"
                },
                {
                    "first": "Diana Felicia",
                    "initial": "D.F.",
                    "last": "de Ara\u00fajo Margarido"
                },
                {
                    "first": "Ana L\u00facia Stone",
                    "initial": "A.L.S.",
                    "last": "de Souza"
                },
                {
                    "first": "Samanta C.G.",
                    "initial": "S.C.G.",
                    "last": "Almeida"
                },
                {
                    "first": "Angela P.",
                    "initial": "A.P.",
                    "last": "Brand\u00e3o"
                },
                {
                    "first": "Lincoln S.",
                    "initial": "L.S.",
                    "last": "Prado"
                },
                {
                    "first": "Maria Luiza L.S.",
                    "initial": "M.L.L.S.",
                    "last": "Guerra"
                },
                {
                    "first": "Glaucia Gama",
                    "initial": "G.G.",
                    "last": "RahalAires"
                },
                {
                    "first": "Orlando Cesar",
                    "initial": "O.C.",
                    "last": "Mantese"
                },
                {
                    "first": "Eitan",
                    "initial": "E.",
                    "last": "Berezin"
                },
                {
                    "first": "Cicero",
                    "initial": "C.",
                    "last": "Dias"
                },
                {
                    "first": "Cristiana",
                    "initial": "C.",
                    "last": "Nascimento"
                },
                {
                    "first": "Joice",
                    "initial": "J.",
                    "last": "Reis"
                },
                {
                    "first": "Ana Lucia",
                    "initial": "A.L.",
                    "last": "Andrade"
                },
                {
                    "first": "Solange",
                    "initial": "S.",
                    "last": "Andrade"
                },
                {
                    "first": "Flavia",
                    "initial": "F.",
                    "last": "Lobos"
                },
                {
                    "first": "Camile",
                    "initial": "C.",
                    "last": "de Moraes"
                },
                {
                    "first": "Eliane Castro",
                    "initial": "E.C.",
                    "last": "de Barros"
                },
                {
                    "first": "M\u00e1rcia Lopes",
                    "initial": "M.L.",
                    "last": "de Carvalho"
                },
                {
                    "first": "Elias Duarte Gon\u00e7alves",
                    "initial": "E.D.G.",
                    "last": "Correiavaccines"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.vaccine.2015.10.007",
            "firstpage": "6145",
            "issn": "0264410X",
            "lastpage": "6148",
            "pmid": "26469718",
            "pub_year": 2015,
            "title": "Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease",
            "volume": "33"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Jukka",
                    "initial": "J.",
                    "last": "Jokinen"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Rinta-Kokko"
                },
                {
                    "first": "Lotta",
                    "initial": "L.",
                    "last": "Siira"
                },
                {
                    "first": "Arto A.",
                    "initial": "A.A.",
                    "last": "Palmu"
                },
                {
                    "first": "Mikko J.",
                    "initial": "M.J.",
                    "last": "Virtanen"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Nohynek"
                },
                {
                    "first": "Anni",
                    "initial": "A.",
                    "last": "Virolainen-Julkunen"
                },
                {
                    "first": "Maija",
                    "initial": "M.",
                    "last": "Toropainen"
                },
                {
                    "first": "J. Pekka",
                    "initial": "J.P.",
                    "last": "Nuorti"
                }
            ],
            "doi": "10.1371/journal.pone.0120290",
            "issn": "19326203",
            "pmid": "25781031",
            "pub_year": 2015,
            "title": "Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children - A population-based study",
            "volume": "10"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Arto A.",
                    "initial": "A.A.",
                    "last": "Palmu"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Rinta-Kokko"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Nohynek"
                },
                {
                    "first": "J. Pekka",
                    "initial": "J.P.",
                    "last": "Nuorti"
                },
                {
                    "first": "Terhi M.",
                    "initial": "T.M.",
                    "last": "Kilpi"
                },
                {
                    "first": "Jukka",
                    "initial": "J.",
                    "last": "Jokinen"
                }
            ],
            "doi": "10.1371/journal.pone.0172690",
            "issn": "19326203",
            "pmid": "28249015",
            "pub_year": 2017,
            "title": "Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study",
            "volume": "12"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Laura L.",
                    "initial": "L.L.",
                    "last": "Hammitt"
                },
                {
                    "first": "Donald O.",
                    "initial": "D.O.",
                    "last": "Akech"
                },
                {
                    "first": "Susan C.",
                    "initial": "S.C.",
                    "last": "Morpeth"
                },
                {
                    "first": "Angela",
                    "initial": "A.",
                    "last": "Karani"
                },
                {
                    "first": "Norbert",
                    "initial": "N.",
                    "last": "Kihuha"
                },
                {
                    "first": "Sammy",
                    "initial": "S.",
                    "last": "Nyongesa"
                },
                {
                    "first": "Tahreni",
                    "initial": "T.",
                    "last": "Bwanaali"
                },
                {
                    "first": "Edward",
                    "initial": "E.",
                    "last": "Mumbo"
                },
                {
                    "first": "Tatu",
                    "initial": "T.",
                    "last": "Kamau"
                },
                {
                    "first": "Shahnaaz K.",
                    "initial": "S.K.",
                    "last": "Sharif"
                },
                {
                    "first": "J. Anthony G.",
                    "initial": "J.A.G.",
                    "last": "Scott"
                }
            ],
            "doi": "10.1016/S2214-109X(14)70224-4",
            "firstpage": "e397",
            "issn": "2214109X",
            "lastpage": "e405",
            "pmid": "25103393",
            "pub_year": 2014,
            "title": "Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: Findings from cross-sectional carriage studies",
            "volume": "2"
        },
        "b0065": null,
        "b0070": null,
        "b0075": {
            "authors": [
                {
                    "first": "Paul K.",
                    "initial": "P.K.",
                    "last": "Drain"
                },
                {
                    "first": "Carib M.",
                    "initial": "C.M.",
                    "last": "Nelson"
                },
                {
                    "first": "John S.",
                    "initial": "J.S.",
                    "last": "Lloyd"
                }
            ],
            "firstpage": "726",
            "issn": "00429686",
            "lastpage": "731",
            "pmid": "14758432",
            "pub_year": 2003,
            "title": "Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries",
            "volume": "81"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Olubukola T.",
                    "initial": "O.T.",
                    "last": "Idoko"
                },
                {
                    "first": "Robert B.",
                    "initial": "R.B.",
                    "last": "Mboizi"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Okoye"
                },
                {
                    "first": "France",
                    "initial": "F.",
                    "last": "Laudat"
                },
                {
                    "first": "Bubacarr",
                    "initial": "B.",
                    "last": "Ceesay"
                },
                {
                    "first": "John Z.",
                    "initial": "J.Z.",
                    "last": "Liang"
                },
                {
                    "first": "Natacha",
                    "initial": "N.",
                    "last": "Le Dren-Narayanin"
                },
                {
                    "first": "Kathrin U.",
                    "initial": "K.U.",
                    "last": "Jansen"
                },
                {
                    "first": "Alejandra",
                    "initial": "A.",
                    "last": "Gurtman"
                },
                {
                    "first": "Kimberly J.",
                    "initial": "K.J.",
                    "last": "Center"
                },
                {
                    "first": "Daniel A.",
                    "initial": "D.A.",
                    "last": "Scott"
                },
                {
                    "first": "Beate",
                    "initial": "B.",
                    "last": "Kampmann"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Roca"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.04.049",
            "firstpage": "3256",
            "issn": "0264410X",
            "lastpage": "3263",
            "pmid": "28479175",
            "pub_year": 2017,
            "title": "Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial",
            "volume": "35"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1586/erv.09.113",
            "firstpage": "1479",
            "issn": "14760584",
            "lastpage": "1500",
            "pmid": "19863240",
            "pub_year": 2009,
            "title": "10-Valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix\u2122",
            "volume": "8"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Stanislav",
                    "initial": "S.",
                    "last": "Plisek"
                }
            ],
            "doi": "10.1517/14712598.8.4.503",
            "firstpage": "503",
            "issn": "14712598",
            "lastpage": "513",
            "pmid": "18352853",
            "pub_year": 2008,
            "title": "Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccines",
            "volume": "8"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Henckaerts"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Goldblatt"
                },
                {
                    "first": "Lindsey",
                    "initial": "L.",
                    "last": "Ashton"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                }
            ],
            "doi": "10.1128/CVI.13.3.356-360.2006",
            "firstpage": "356",
            "issn": "15566811",
            "lastpage": "360",
            "pmid": "16522777",
            "pub_year": 2006,
            "title": "Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera",
            "volume": "13"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                },
                {
                    "first": "Carl E.",
                    "initial": "C.E.",
                    "last": "Frasch"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "K\u00e4yhty"
                },
                {
                    "first": "Pascal",
                    "initial": "P.",
                    "last": "Lestrate"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Henckaerts"
                }
            ],
            "doi": "10.1128/CVI.00289-09",
            "firstpage": "134",
            "issn": "15566811",
            "lastpage": "142",
            "pmid": "19889940",
            "pub_year": 2010,
            "title": "Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines",
            "volume": "17"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Henckaerts"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Durant"
                },
                {
                    "first": "Dany",
                    "initial": "D.",
                    "last": "De Grave"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                }
            ],
            "doi": "10.1016/j.vaccine.2006.09.029",
            "firstpage": "2518",
            "issn": "0264410X",
            "lastpage": "2527",
            "pmid": "17034907",
            "pub_year": 2007,
            "title": "Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children",
            "volume": "25"
        },
        "b0110": null,
        "b0115": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Jacek",
                    "initial": "J.",
                    "last": "Wysocki"
                },
                {
                    "first": "Bertrand",
                    "initial": "B.",
                    "last": "Chevallier"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Karvonen"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Czajka"
                },
                {
                    "first": "Jean Pierre",
                    "initial": "J.P.",
                    "last": "Ars\u00e8ne"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Lommel"
                },
                {
                    "first": "Ilse",
                    "initial": "I.",
                    "last": "Dieussaert"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1097/INF.0b013e318199f8ef",
            "firstpage": "S66",
            "issn": "08913668",
            "lastpage": "S76",
            "pmid": "19325449",
            "pub_year": 2009,
            "title": "Immunogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine",
            "volume": "28"
        },
        "b0120": null,
        "b0125": {
            "authors": [
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Lalwani"
                },
                {
                    "first": "Sukanta",
                    "initial": "S.",
                    "last": "Chatterjee"
                },
                {
                    "first": "Jugesh",
                    "initial": "J.",
                    "last": "Chhatwal"
                },
                {
                    "first": "Valsan P.",
                    "initial": "V.P.",
                    "last": "Verghese"
                },
                {
                    "first": "Shailesh",
                    "initial": "S.",
                    "last": "Mehta"
                },
                {
                    "first": "Fakrudeen",
                    "initial": "F.",
                    "last": "Shafi"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Moreira"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.4161/hv.19287",
            "firstpage": "612",
            "issn": "2164554X",
            "lastpage": "622",
            "pmid": "22634448",
            "pub_year": 2012,
            "title": "Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: A single-blind, randomized, controlled study",
            "volume": "8"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Lalwani"
                },
                {
                    "first": "Sukanta",
                    "initial": "S.",
                    "last": "Chatterjee"
                },
                {
                    "first": "Jugesh",
                    "initial": "J.",
                    "last": "Chhatwal"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Simon"
                },
                {
                    "first": "Sudheer",
                    "initial": "S.",
                    "last": "Ravula"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Francois"
                },
                {
                    "first": "Shailesh",
                    "initial": "S.",
                    "last": "Mehta"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "Strezova"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1128/CVI.00068-14",
            "firstpage": "1292",
            "issn": "15566811",
            "lastpage": "1300",
            "pmid": "25008901",
            "pub_year": 2014,
            "title": "Randomized, open-label study of the impact of age on booster responses to the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in children in India",
            "volume": "21"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Alassane",
                    "initial": "A.",
                    "last": "Dicko"
                },
                {
                    "first": "Olumuyiwa O.",
                    "initial": "O.O.",
                    "last": "Odusanya"
                },
                {
                    "first": "Abdoulbaki I.",
                    "initial": "A.I.",
                    "last": "Diallo"
                },
                {
                    "first": "Gaoussou",
                    "initial": "G.",
                    "last": "Santara"
                },
                {
                    "first": "Amadou",
                    "initial": "A.",
                    "last": "Barry"
                },
                {
                    "first": "Amagana",
                    "initial": "A.",
                    "last": "Dolo"
                },
                {
                    "first": "Aminata",
                    "initial": "A.",
                    "last": "Diallo"
                },
                {
                    "first": "Yetunde A.",
                    "initial": "Y.A.",
                    "last": "Kuyinu"
                },
                {
                    "first": "Omolara A.",
                    "initial": "O.A.",
                    "last": "Kehinde"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Fran\u00e7ois"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "Juan P.",
                    "initial": "J.P.",
                    "last": "Yarzabal"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Moreira"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1186/1471-2458-11-882",
            "issn": "14712458",
            "pmid": "22112189",
            "pub_year": 2011,
            "title": "Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: A randomized controlled trial",
            "volume": "11"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Alassane",
                    "initial": "A.",
                    "last": "Dicko"
                },
                {
                    "first": "Gaoussou",
                    "initial": "G.",
                    "last": "Santara"
                },
                {
                    "first": "Almahamoudou",
                    "initial": "A.",
                    "last": "Mahamar"
                },
                {
                    "first": "Youssoufa",
                    "initial": "Y.",
                    "last": "Sidibe"
                },
                {
                    "first": "Amadou",
                    "initial": "A.",
                    "last": "Barry"
                },
                {
                    "first": "Yahia",
                    "initial": "Y.",
                    "last": "Dicko"
                },
                {
                    "first": "Aminata",
                    "initial": "A.",
                    "last": "Diallo"
                },
                {
                    "first": "Amagana",
                    "initial": "A.",
                    "last": "Dolo"
                },
                {
                    "first": "Ogobara",
                    "initial": "O.",
                    "last": "Doumbo"
                },
                {
                    "first": "Fakrudeen",
                    "initial": "F.",
                    "last": "Shafi"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Francois"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "Strezova"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.4161/hv.22692",
            "firstpage": "382",
            "issn": "21645515",
            "lastpage": "388",
            "pmid": "23291945",
            "pub_year": 2013,
            "title": "Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children",
            "volume": "9"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Aderonke",
                    "initial": "A.",
                    "last": "Odutola"
                },
                {
                    "first": "Martin O.C.",
                    "initial": "M.O.C.",
                    "last": "Ota"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Antonio"
                },
                {
                    "first": "Ezra O.",
                    "initial": "E.O.",
                    "last": "Ogundare"
                },
                {
                    "first": "Yauba",
                    "initial": "Y.",
                    "last": "Saidu"
                },
                {
                    "first": "Ebenezer",
                    "initial": "E.",
                    "last": "Foster-Nyarko"
                },
                {
                    "first": "Patrick K.",
                    "initial": "P.K.",
                    "last": "Owiafe"
                },
                {
                    "first": "Fatima",
                    "initial": "F.",
                    "last": "Ceesay"
                },
                {
                    "first": "Archibald",
                    "initial": "A.",
                    "last": "Worwui"
                },
                {
                    "first": "Olubukola T.",
                    "initial": "O.T.",
                    "last": "Idoko"
                },
                {
                    "first": "Olumuyiwa",
                    "initial": "O.",
                    "last": "Owolabi"
                },
                {
                    "first": "Abdoulie",
                    "initial": "A.",
                    "last": "Bojang"
                },
                {
                    "first": "Sheikh",
                    "initial": "S.",
                    "last": "Jarju"
                },
                {
                    "first": "Isatou",
                    "initial": "I.",
                    "last": "Drammeh"
                },
                {
                    "first": "Beate",
                    "initial": "B.",
                    "last": "Kampmann"
                },
                {
                    "first": "Brian M.",
                    "initial": "B.M.",
                    "last": "Greenwood"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Alderson"
                },
                {
                    "first": "Magali",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Devos"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Schoonbroodt"
                },
                {
                    "first": "Kristien",
                    "initial": "K.",
                    "last": "Swinnen"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "Kurt",
                    "initial": "K.",
                    "last": "Dobbelaere"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.03.071",
            "firstpage": "2531",
            "issn": "0264410X",
            "lastpage": "2542",
            "pmid": "28389097",
            "pub_year": 2017,
            "title": "Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study",
            "volume": "35"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Chang Hwi",
                    "initial": "C.H.",
                    "last": "Kim"
                },
                {
                    "first": "Jung Soo",
                    "initial": "J.S.",
                    "last": "Kim"
                },
                {
                    "first": "Sung Ho",
                    "initial": "S.H.",
                    "last": "Cha"
                },
                {
                    "first": "Kwang Nam",
                    "initial": "K.N.",
                    "last": "Kim"
                },
                {
                    "first": "Jong Duck",
                    "initial": "J.D.",
                    "last": "Kim"
                },
                {
                    "first": "Kyung Yil",
                    "initial": "K.Y.",
                    "last": "Lee"
                },
                {
                    "first": "Hwang Min",
                    "initial": "H.M.",
                    "last": "Kim"
                },
                {
                    "first": "Jong Hyun",
                    "initial": "J.H.",
                    "last": "Kim"
                },
                {
                    "first": "Sang",
                    "initial": "S.",
                    "last": "Hyuk"
                },
                {
                    "first": "Jung Yun",
                    "initial": "J.Y.",
                    "last": "Hong"
                },
                {
                    "first": "Su Eun",
                    "initial": "S.E.",
                    "last": "Park"
                },
                {
                    "first": "Yun Kyung",
                    "initial": "Y.K.",
                    "last": "Kim"
                },
                {
                    "first": "Nam Hee",
                    "initial": "N.H.",
                    "last": "Kim"
                },
                {
                    "first": "Aur\u00e9lie",
                    "initial": "A.",
                    "last": "Fanic"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Ruiz-Gui\u00f1az\u00f9"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Moreira"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                },
                {
                    "first": "Kyung Hyo",
                    "initial": "K.H.",
                    "last": "Kim"
                }
            ],
            "doi": "10.1097/INF.0b013e31822a8541",
            "firstpage": "e235",
            "issn": "08913668",
            "lastpage": "e243",
            "pmid": "21817957",
            "pub_year": 2011,
            "title": "Response to primary and booster vaccination with 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine in Korean infants",
            "volume": "30"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Fong S.",
                    "initial": "F.S.",
                    "last": "Lim"
                },
                {
                    "first": "Mia T.",
                    "initial": "M.T.",
                    "last": "Koh"
                },
                {
                    "first": "Kah K.",
                    "initial": "K.K.",
                    "last": "Tan"
                },
                {
                    "first": "Poh C.",
                    "initial": "P.C.",
                    "last": "Chan"
                },
                {
                    "first": "Chia Y.",
                    "initial": "C.Y.",
                    "last": "Chong"
                },
                {
                    "first": "Yeo W.",
                    "initial": "Y.W.",
                    "last": "Shung Yehudi"
                },
                {
                    "first": "Yee L.",
                    "initial": "Y.L.",
                    "last": "Teoh"
                },
                {
                    "first": "Fakrudeen",
                    "initial": "F.",
                    "last": "Shafi"
                },
                {
                    "first": "Marjan",
                    "initial": "M.",
                    "last": "Hezareh"
                },
                {
                    "first": "Kristien",
                    "initial": "K.",
                    "last": "Swinnen"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1186/1471-2334-14-530",
            "issn": "14712334",
            "pmid": "25278086",
            "pub_year": 2014,
            "title": "A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia",
            "volume": "14"
        },
        "b0160": null
    },
    "body_text": [
        {
            "endOffset": 42153,
            "parents": [],
            "secId": "s0090",
            "sentence": "The booster dose was given at 9 months of age to allow co-administration with the routine measles vaccination, which is earlier than the usual PCV booster vaccination in the second year of life.",
            "startOffset": 41959,
            "title": "Discussion"
        },
        {
            "endOffset": 28379,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "Solicited adverse events (AEs) at the injection site (pain, redness and swelling) and general AEs (drowsiness, fever, irritability and loss of appetite) were reported on diary cards within 4 days post-vaccination.",
            "startOffset": 28166,
            "title": "Reactogenicity and safety assessment"
        },
        {
            "endOffset": 35385,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0080",
            "sentence": "The most commonly reported unsolicited AEs were diarrhea (0.8% of doses in the 4DV group; 0.7% of doses in the 1DV group), nasopharyngitis (0.9% of doses in the 1DV group) and pneumonia (0.7% of doses in the 1DV group).",
            "startOffset": 35166,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 26775,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "Reactogenicity and safety following PHiD-CV 4-dose vial vaccination were also assessed.",
            "startOffset": 26688,
            "title": "Objectives"
        },
        {
            "endOffset": 33292,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0070",
            "sentence": "One month post-booster, for each VT at least 98.6% of infants had antibody concentrations \u22650.2 \u00b5g/mL, except serotypes 6B and 23F.",
            "startOffset": 33162,
            "title": "Booster vaccination phase"
        },
        {
            "endOffset": 37258,
            "parents": [],
            "secId": "s0090",
            "sentence": "This study demonstrated non-inferiority of the PHiD-CV 4-dose vial versus the PHiD-CV 1-dose vial in terms of antibody GMCs for each VT and 19A after completion of a 3-dose primary vaccination in infants at ages 6, 10 and 18 weeks.",
            "startOffset": 37027,
            "title": "Discussion"
        },
        {
            "endOffset": 38826,
            "parents": [],
            "secId": "s0090",
            "sentence": "No differences were observed for these parameters for each VT and 19A between 4DV and 1DV groups.",
            "startOffset": 38729,
            "title": "Discussion"
        },
        {
            "endOffset": 31866,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The elapsed time from PHiD-CV 4-dose vial opening to use of the last vial-dose ranged between 0 and 7 days during the primary vaccination and between 0 and 23 days during the booster vaccination.",
            "startOffset": 31671,
            "title": "Use of the PHiD-CV 4-dose vial"
        },
        {
            "endOffset": 38088,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 38087,
                    "startOffset": 38080
                },
                "b0120": {
                    "endOffset": 38087,
                    "startOffset": 38080
                }
            },
            "secId": "s0090",
            "sentence": "Similarly, the criteria used for licensure and prequalification of the 4-dose presentation of PCV13 containing preservative included non-inferiority in terms of a 2-fold limit for anti-pneumococcal antibody GMCs after 3-dose primary vaccination [16,24].",
            "startOffset": 37835,
            "title": "Discussion"
        },
        {
            "endOffset": 30678,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Percentages of doses followed by solicited or unsolicited AEs were tabulated with exact 95% CIs.",
            "startOffset": 30582,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 41958,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 41957,
                    "startOffset": 41953
                }
            },
            "secId": "s0090",
            "sentence": "Although booster vaccination is not included in the EPI schedule, infants received a PHiD-CV booster dose as per current recommendations [13].",
            "startOffset": 41816,
            "title": "Discussion"
        },
        {
            "endOffset": 42887,
            "parents": [],
            "secId": "s0095",
            "sentence": "This study demonstrated immunologic non-inferiority of the PHiD-CV 4-dose vial presentation (with preservative) compared to the PHiD-CV 1-dose vial presentation (preservative-free).",
            "startOffset": 42706,
            "title": "Conclusion"
        },
        {
            "endOffset": 23278,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 23277,
                    "startOffset": 23273
                }
            },
            "secId": "s0005",
            "sentence": "GSK has developed a 4-dose vial presentation of PHiD-CV with addition of a preservative (2-phenoxyethanol) to control potential microbial contamination, allowing vaccine use up to 28 days after opening as per WHO multi-dose vial policy [14].",
            "startOffset": 23037,
            "title": "Introduction"
        },
        {
            "endOffset": 43074,
            "parents": [],
            "secId": "s0095",
            "sentence": "Following primary vaccination at 6, 10 and 18 weeks of age and booster vaccination at 9 months of age, immune responses elicited by PHiD-CV 4-dose and 1-dose vial were in similar ranges.",
            "startOffset": 42888,
            "title": "Conclusion"
        },
        {
            "endOffset": 26920,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "Blood samples were collected 1 and 5 months post-primary vaccination, and 1 month post-booster vaccination (Fig. S1).",
            "startOffset": 26803,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 30708,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "SAE occurrence was described.",
            "startOffset": 30679,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 40737,
            "parents": [],
            "secId": "s0090",
            "sentence": "The faster use observed during primary vaccination is expected in the settings and conditions of mass vaccination in developing countries for which this presentation is intended.",
            "startOffset": 40559,
            "title": "Discussion"
        },
        {
            "endOffset": 22319,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 22318,
                    "startOffset": 22315
                }
            },
            "secId": "s0005",
            "sentence": "Currently, PCVs are supplied to developing countries via the Global Alliance for Vaccines and Immunization (GAVI) in high volume at affordable prices [3].",
            "startOffset": 22165,
            "title": "Introduction"
        },
        {
            "endOffset": 36386,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0085",
            "sentence": "Grade 3 irritability considered as vaccination-related was reported for 1 infant (after 0.7% of doses) in the 4DV group.",
            "startOffset": 36266,
            "title": "Booster vaccination phase"
        },
        {
            "endOffset": 29748,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Immunogenicity analyses were performed on the ATP cohorts for immunogenicity adapted for primary and booster vaccination.",
            "startOffset": 29627,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 33424,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0070",
            "sentence": "For serotypes 6A and 19A, at least 80.8% and 90.7% of infants in both groups, respectively, had antibody concentrations \u22650.2 \u00b5g/mL.",
            "startOffset": 33293,
            "title": "Booster vaccination phase"
        },
        {
            "endOffset": 39056,
            "parents": [],
            "secId": "s0090",
            "sentence": "For most serotypes, post-booster increases in OPA GMTs were also observed.",
            "startOffset": 38982,
            "title": "Discussion"
        },
        {
            "endOffset": 28829,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "For literate parents/LARs, fieldworkers visited each infant every day within the 4 days after PHiD-CV vaccination, but the parents/LARs filled in the diary cards.",
            "startOffset": 28667,
            "title": "Reactogenicity and safety assessment"
        },
        {
            "endOffset": 42381,
            "parents": [],
            "secId": "s0090",
            "sentence": "The study also had limitations.",
            "startOffset": 42350,
            "title": "Discussion"
        },
        {
            "endOffset": 43587,
            "parents": [],
            "secId": "s0100",
            "sentence": "GlaxoSmithKline Biologicals SA also took responsibility for all costs associated with the development and publishing of the present manuscript.",
            "startOffset": 43444,
            "title": "Funding"
        },
        {
            "endOffset": 25764,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "Consecutive vial-doses from the PHiD-CV 4-dose presentation were used for vaccination of infants randomized to receive this vaccine (0.5 mL per dose).",
            "startOffset": 25614,
            "title": "Study vaccines"
        },
        {
            "endOffset": 27320,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The percentage of children with antibody concentrations \u22650.2 \u03bcg/mL are presented here.",
            "startOffset": 27234,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 34878,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0080",
            "sentence": "Grade 3 solicited general AEs considered as vaccination-related were reported after 0.4% (drowsiness) to 3.8% (irritability) of doses in the 4DV group and after 1.1% (loss of appetite) to 3.1% (irritability) of doses in the 1DV group.",
            "startOffset": 34644,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 41257,
            "parents": [],
            "secId": "s0090",
            "sentence": "Therefore, safety and immunogenicity data generated in this study are representative of a 4-dose vial used up to the last dose, and any vial dose can be given at any vaccination visit.",
            "startOffset": 41073,
            "title": "Discussion"
        },
        {
            "endOffset": 22164,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 22163,
                    "startOffset": 22158
                },
                "b0010": {
                    "endOffset": 22163,
                    "startOffset": 22158
                }
            },
            "secId": "s0005",
            "sentence": "The invasive pneumococcal disease (IPD) burden has been substantially reduced worldwide since the introduction of pneumococcal conjugate vaccines (PCVs) in national immunization programs (NIPs) [1,2].",
            "startOffset": 21964,
            "title": "Introduction"
        },
        {
            "endOffset": 30431,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Comparison of the PHiD-CV 4-dose vial versus PHiD-CV 1-dose vial in terms of non-inferiority was demonstrated if the upper limit (UL) of the 2-sided 95% CI of the GMC ratios (1DV group/4DV group) was less than 2-fold for each VT (primary confirmatory objective) and vaccine-related serotype 19A (secondary confirmatory objective).",
            "startOffset": 30101,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 34422,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0080",
            "sentence": "No large swelling reactions were reported.",
            "startOffset": 34380,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 36505,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0085",
            "sentence": "No SAEs were reported post-booster vaccination.",
            "startOffset": 36458,
            "title": "Booster vaccination phase"
        },
        {
            "endOffset": 33572,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0070",
            "sentence": "Antibody GMCs were higher 1 month poster-booster compared to post-primary vaccination, and within similar ranges for each VT, 6A and 19A (Table 2).",
            "startOffset": 33425,
            "title": "Booster vaccination phase"
        },
        {
            "endOffset": 42695,
            "parents": [],
            "secId": "s0090",
            "sentence": "Furthermore, the OPA and protein D responses were assessed in a subset (50%) of subjects.",
            "startOffset": 42606,
            "title": "Discussion"
        },
        {
            "endOffset": 32361,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0065",
            "sentence": "For vaccine-related serotypes 6A and 19A, at least 58.2% and 80.1% of infants in both groups, respectively, had antibody concentrations \u22650.2 \u03bcg/mL.",
            "startOffset": 32214,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 40955,
            "parents": [],
            "secId": "s0090",
            "sentence": "The strengths of this study include the confirmatory objective with appropriate design: well-recognized, predefined non-inferiority criteria in a two-arm trial design comparing PHiD-CV 4-dose vial with the 1-dose vial.",
            "startOffset": 40737,
            "title": "Discussion"
        },
        {
            "endOffset": 42350,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 42349,
                    "startOffset": 42345
                }
            },
            "secId": "s0090",
            "sentence": "A clinical study in India did not suggest differences in terms of antibody GMCs between children receiving a PHiD-CV booster dose at 9\u201312 or 15\u201318 months of age following primary vaccination [26].",
            "startOffset": 42154,
            "title": "Discussion"
        },
        {
            "endOffset": 22663,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 22511,
                    "startOffset": 22506
                },
                "b0025": {
                    "endOffset": 22511,
                    "startOffset": 22506
                },
                "b0030": {
                    "endOffset": 22662,
                    "startOffset": 22656
                },
                "b0035": {
                    "endOffset": 22662,
                    "startOffset": 22656
                },
                "b0040": {
                    "endOffset": 22662,
                    "startOffset": 22656
                },
                "b0045": {
                    "endOffset": 22662,
                    "startOffset": 22656
                },
                "b0050": {
                    "endOffset": 22662,
                    "startOffset": 22656
                },
                "b0055": {
                    "endOffset": 22662,
                    "startOffset": 22656
                },
                "b0060": {
                    "endOffset": 22662,
                    "startOffset": 22656
                },
                "b0065": {
                    "endOffset": 22662,
                    "startOffset": 22656
                }
            },
            "secId": "s0005",
            "sentence": "The efficacy and effectiveness/impact of pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV, GSK) against IPD have been demonstrated in clinical trials [4,5] and in post-marketing studies, including evidence for vaccine effectiveness against vaccine serotypes (VT) and vaccine-related serotype 19A IPD [6\u201313].",
            "startOffset": 22319,
            "title": "Introduction"
        },
        {
            "endOffset": 23680,
            "parents": [],
            "secId": "s0005",
            "sentence": "Here, we present the immunologic non-inferiority of the PHiD-CV 4-dose vial in infants compared to the PHiD-CV 1-dose vial after primary vaccination.",
            "startOffset": 23531,
            "title": "Introduction"
        },
        {
            "endOffset": 33931,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0070",
            "sentence": "For most serotypes, OPA GMTs were higher post-booster compared to post-primary vaccination, and within similar ranges between groups for each VT, 6A and 19A (Table 3).",
            "startOffset": 33764,
            "title": "Booster vaccination phase"
        },
        {
            "endOffset": 24951,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Overall, the study was conducted in accordance with the principles of Good Clinical Practice, Declaration of Helsinki and all applicable regulatory requirements.",
            "startOffset": 24790,
            "title": "Study design and population"
        },
        {
            "endOffset": 38318,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 38259,
                    "startOffset": 38254
                },
                "b0025": {
                    "endOffset": 38259,
                    "startOffset": 38254
                },
                "b0030": {
                    "endOffset": 38317,
                    "startOffset": 38311
                },
                "b0035": {
                    "endOffset": 38317,
                    "startOffset": 38311
                },
                "b0040": {
                    "endOffset": 38317,
                    "startOffset": 38311
                },
                "b0045": {
                    "endOffset": 38317,
                    "startOffset": 38311
                },
                "b0050": {
                    "endOffset": 38317,
                    "startOffset": 38311
                },
                "b0055": {
                    "endOffset": 38317,
                    "startOffset": 38311
                },
                "b0060": {
                    "endOffset": 38317,
                    "startOffset": 38311
                }
            },
            "secId": "s0090",
            "sentence": "Demonstration of immunologic non-inferiority of the PHiD-CV 4-dose versus the PHiD-CV 1-dose vial supports the inference of efficacy/effectiveness in clinical trials [4,5] and effectiveness/impact in post-marketing studies [6\u201312].",
            "startOffset": 38088,
            "title": "Discussion"
        },
        {
            "endOffset": 26059,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "During primary vaccination, both PHiD-CV and DTPw-HBV/Hib were administered as intramuscular injections into the anterolateral thigh on the right and left sides, respectively.",
            "startOffset": 25884,
            "title": "Study vaccines"
        },
        {
            "endOffset": 23821,
            "parents": [],
            "secId": "s0005",
            "sentence": "The immunogenicity, reactogenicity and safety after primary and booster vaccination with PHiD-CV 4-dose and 1-dose vials were also assessed.",
            "startOffset": 23681,
            "title": "Introduction"
        },
        {
            "endOffset": 33162,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0070",
            "sentence": "Five months post-primary vaccination (pre-booster), the persistence of the immune responses following PHiD-CV 4-dose vial vaccination was similar to that observed after PHiD-CV 1-dose vial vaccination, for each VT and vaccine-related serotypes 6A and 19A (Tables 2 and 3).",
            "startOffset": 32890,
            "title": "Booster vaccination phase"
        },
        {
            "endOffset": 25613,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "The investigational PHiD-CV 4-dose vial contained the same conjugated capsular polysaccharides as the PHiD-CV 1-dose vial but with the preservative 2-phenoxyethanol.",
            "startOffset": 25448,
            "title": "Study vaccines"
        },
        {
            "endOffset": 31441,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Of these, 295 were included in the ATP cohort for immunogenicity for booster vaccination: 151 in the 4DV group and 144 in the 1DV group (Fig. 1).",
            "startOffset": 31296,
            "title": "Study population"
        },
        {
            "endOffset": 34110,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0070",
            "sentence": "One month post-booster, all infants had anti-protein D antibody concentrations \u2265153 EL.U/mL and antibody GMCs were within similar ranges between the 4DV and 1DV groups (Table S2).",
            "startOffset": 33931,
            "title": "Booster vaccination phase"
        },
        {
            "endOffset": 38981,
            "parents": [],
            "secId": "s0090",
            "sentence": "Post-booster vaccination with PHiD-CV 4-dose at 9 months old, increases in antibody GMCs (for all VT, and 19A) were observed, indicating effective priming.",
            "startOffset": 38826,
            "title": "Discussion"
        },
        {
            "endOffset": 39709,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 39682,
                    "startOffset": 39675
                },
                "b0130": {
                    "endOffset": 39682,
                    "startOffset": 39675
                },
                "b0135": {
                    "endOffset": 39708,
                    "startOffset": 39701
                },
                "b0140": {
                    "endOffset": 39708,
                    "startOffset": 39701
                }
            },
            "secId": "s0090",
            "sentence": "Overall, incidences of solicited AEs seemed to be generally lower than in previous studies conducted in India [25,26], Mali and Nigeria [27,28].",
            "startOffset": 39565,
            "title": "Discussion"
        },
        {
            "endOffset": 24709,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "A protocol summary is available at http://www.gsk-clinicalstudyregister.com (study ID 200799).",
            "startOffset": 24615,
            "title": "Study design and population"
        },
        {
            "endOffset": 36717,
            "parents": [],
            "secId": "s0090",
            "sentence": "The use of a multi-dose vial would improve the logistics of PCV immunization programs, by reducing the required volume of cold chain and increasing the storage time, especially in developing countries.",
            "startOffset": 36516,
            "title": "Discussion"
        },
        {
            "endOffset": 41815,
            "parents": [],
            "secId": "s0090",
            "sentence": "This non-classical EPI schedule might be followed by other countries to allow additional vaccinations such as IPV at 14 weeks.",
            "startOffset": 41689,
            "title": "Discussion"
        },
        {
            "endOffset": 29050,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "All solicited injection site reactions were considered as causally related to vaccination.",
            "startOffset": 28960,
            "title": "Reactogenicity and safety assessment"
        },
        {
            "endOffset": 32776,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0065",
            "sentence": "All infants had anti-protein D antibody concentrations \u2265153 EL.U/mL 1 month post-primary vaccination.",
            "startOffset": 32675,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 43753,
            "parents": [],
            "secId": "s0105",
            "sentence": "Potential conflict of interest: The institution of KZ, FZ, S FZ, AA and SBF received funding from the GSK group of companies for the conduct of this study.",
            "startOffset": 43598,
            "title": "Disclosures"
        },
        {
            "endOffset": 43317,
            "parents": [],
            "secId": "s0095",
            "sentence": "The PHiD-CV 4-dose vial would help improve access and coverage in resource-limited countries, and may enable more children to become protected against pneumococcal disease.",
            "startOffset": 43145,
            "title": "Conclusion"
        },
        {
            "endOffset": 36023,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0085",
            "sentence": "During the 4-day post-vaccination period, the most frequently reported solicited PHiD-CV injection site reactions and general AEs were swelling and irritability, respectively (Fig. 3B).",
            "startOffset": 35838,
            "title": "Booster vaccination phase"
        },
        {
            "endOffset": 23037,
            "parents": [],
            "secId": "s0005",
            "sentence": "However, vaccine vials should be discarded within maximum 6 h after opening as this presentation is preservative-free.",
            "startOffset": 22919,
            "title": "Introduction"
        },
        {
            "endOffset": 38455,
            "parents": [],
            "secId": "s0090",
            "sentence": "This suggests that the PHiD-CV 4-dose vial can provide a similar protection against pneumococcal infections as the licensed 1-dose vial.",
            "startOffset": 38319,
            "title": "Discussion"
        },
        {
            "endOffset": 37027,
            "parents": [],
            "secId": "s0090",
            "sentence": "We compared the immunogenicity, reactogenicity and safety of the 4-dose vial to the 1-dose vial.",
            "startOffset": 36931,
            "title": "Discussion"
        },
        {
            "endOffset": 37675,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 37674,
                    "startOffset": 37670
                }
            },
            "secId": "s0090",
            "sentence": "We have applied the non-inferiority criteria in terms of anti-pneumococcal antibody GMCs measured by ELISA as previously used to demonstrate PHiD-CV lot-to-lot consistency [23].",
            "startOffset": 37498,
            "title": "Discussion"
        },
        {
            "endOffset": 39532,
            "parents": [],
            "secId": "s0090",
            "sentence": "The PHiD-CV 4-dose vial (with preservative) had an acceptable reactogenicity profile, similar to the one of the PHiD-CV 1-dose vial (preservative-free) in infants following a 3-dose primary vaccination at 6, 10 and 18 weeks (given with DTPw-HBV/Hib at 6 and 10 weeks) and following booster vaccination at 9 months.",
            "startOffset": 39218,
            "title": "Discussion"
        },
        {
            "endOffset": 41391,
            "parents": [],
            "secId": "s0090",
            "sentence": "Another strength was that this study was conducted in a GAVI-eligible country in which the 4-dose presentation is planned to be used.",
            "startOffset": 41258,
            "title": "Discussion"
        },
        {
            "endOffset": 31516,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Baseline demographic characteristics were similar between groups (Table 1).",
            "startOffset": 31441,
            "title": "Study population"
        },
        {
            "endOffset": 34379,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0080",
            "sentence": "During the 4-day post-vaccination period, pain was the most frequently reported solicited PHiD-CV injection site reaction and irritability was the most frequently reported solicited general AE (Fig. 3A).",
            "startOffset": 34176,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 35453,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0080",
            "sentence": "None of the unsolicited AEs were considered as vaccination-related.",
            "startOffset": 35386,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 30101,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 30100,
                    "startOffset": 30093
                },
                "b0105": {
                    "endOffset": 30100,
                    "startOffset": 30093
                }
            },
            "secId": "s0040",
            "sentence": "Antibody GMCs and OPA GMTs were calculated as described previously [20,21].",
            "startOffset": 30026,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 25448,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0085": {
                    "endOffset": 25447,
                    "startOffset": 25443
                }
            },
            "secId": "s0020",
            "sentence": "The licensed PHiD-CV 1-dose vial (Synflorix, GSK) was a preservative-free suspension containing capsular polysaccharides of 10 pneumococcal serotypes: 1, 4, 5, 6B, 7F, 9V, 14 and 23F conjugated to non-typeable H. influenzae protein D, 18C to tetanus toxoid and 19F to diphtheria toxoid as described previously [17].",
            "startOffset": 25133,
            "title": "Study vaccines"
        },
        {
            "endOffset": 39899,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 39814,
                    "startOffset": 39807
                },
                "b0130": {
                    "endOffset": 39814,
                    "startOffset": 39807
                },
                "b0145": {
                    "endOffset": 39834,
                    "startOffset": 39830
                },
                "b0150": {
                    "endOffset": 39898,
                    "startOffset": 39891
                },
                "b0155": {
                    "endOffset": 39898,
                    "startOffset": 39891
                }
            },
            "secId": "s0090",
            "sentence": "Rates of reported unsolicited AEs were in line with other studies with PHiD-CV conducted in India [25,26] and the Gambia [29], and generally lower than in other developing countries [30,31].",
            "startOffset": 39709,
            "title": "Discussion"
        },
        {
            "endOffset": 39218,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 39217,
                    "startOffset": 39213
                }
            },
            "secId": "s0090",
            "sentence": "These findings support the PHiD-CV 4-dose vial boostability, which is also part of WHO recommendation to assess new PCVs for licensure and prequalification [22].",
            "startOffset": 39057,
            "title": "Discussion"
        },
        {
            "endOffset": 41575,
            "parents": [],
            "secId": "s0090",
            "sentence": "In addition to PHiD-CV 4-dose vial, infants also received common childhood vaccines as in a real-life setting and per Expanded Program on Immunization (EPI) schedule at 6\u201310\u201314 weeks.",
            "startOffset": 41392,
            "title": "Discussion"
        },
        {
            "endOffset": 30494,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "The latter was only assessed if the primary objective was met.",
            "startOffset": 30432,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 41072,
            "parents": [],
            "secId": "s0090",
            "sentence": "Furthermore, use of each dose from the 4-dose vial was evenly repartitioned among primary and booster vaccine doses.",
            "startOffset": 40956,
            "title": "Discussion"
        },
        {
            "endOffset": 29852,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Details regarding infant eligibility for inclusion in these cohorts are shown in supplementary text S4.",
            "startOffset": 29749,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 27814,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "Functional immune responses (opsonophagocytic activity, OPA) to each VT and vaccine-related serotypes 6A and 19A were measured in a selected subset (first 50% of infants recruited in each month of enrolment throughout the study) by a validated multiplex OPA assay (at the University College of London, Institute of Child Health, London, United Kingdom).",
            "startOffset": 27461,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 23530,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 23425,
                    "startOffset": 23421
                },
                "b0080": {
                    "endOffset": 23529,
                    "startOffset": 23525
                }
            },
            "secId": "s0005",
            "sentence": "This would further enhance logistics and adherence to immunization programs in developing countries, as in place for other pediatric vaccines [15], including the recently WHO-qualified 13-valent pneumococcal conjugate vaccine (PCV13) 4-dose vial [16].",
            "startOffset": 23279,
            "title": "Introduction"
        },
        {
            "endOffset": 24276,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Infants aged 6\u201310 weeks were randomized 1:1 to receive either PHiD-CV 4-dose vial (4DV group) or PHiD-CV 1-dose vial (1DV group) administered in a 3 + 1 schedule at ages 6, 10 and 18 weeks (primary vaccination) and 9 months (booster vaccination) (Fig. S1).",
            "startOffset": 24020,
            "title": "Study design and population"
        },
        {
            "endOffset": 27461,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 27460,
                    "startOffset": 27456
                }
            },
            "secId": "s0030",
            "sentence": "This threshold is equivalent to an antibody concentration \u22650.35 \u00b5g/mL as measured by the non-22F-ELISA of the WHO reference laboratory [20].",
            "startOffset": 27321,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 31295,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "During the booster vaccination phase, 297 infants were included in the TVC and completed the study (152 in the 4DV group and 145 in the 1DV group).",
            "startOffset": 31148,
            "title": "Study population"
        },
        {
            "endOffset": 27233,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0095": {
                    "endOffset": 27232,
                    "startOffset": 27228
                }
            },
            "secId": "s0030",
            "sentence": "Serotype-specific pneumococcal immunoglobulin G (IgG) antibodies against VT and vaccine-related serotypes 6A and 19A were measured using the enzyme linked immunosorbent assay with serotype 22F polysaccharide adsorption (22F-ELISA) (at the laboratory N\u00e9omed-Labs Inc, Quebec, Canada), as previously described [19].",
            "startOffset": 26920,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 32213,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0065",
            "sentence": "For each VT, the percentage of infants with antibody concentrations \u22650.2 \u03bcg/mL was at least 97.9%, except for serotypes 6B and 23F.",
            "startOffset": 32082,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 28666,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "For the illiterate parents/LARs, fieldworkers visited each infant every day within the 31 days after PHiD-CV vaccination and recorded their signs and symptoms on the diary cards.",
            "startOffset": 28488,
            "title": "Reactogenicity and safety assessment"
        },
        {
            "endOffset": 37497,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 37496,
                    "startOffset": 37492
                }
            },
            "secId": "s0090",
            "sentence": "Due to the lack of a clear correlate of protection against IPD, the WHO recognizes immunologic non-inferiority post-primary vaccination as one of the serological criteria for assessment of new PCVs for licensure and prequalification [22].",
            "startOffset": 37259,
            "title": "Discussion"
        },
        {
            "endOffset": 30581,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Reactogenicity and safety analyses were performed on the total vaccinated cohort (TVC).",
            "startOffset": 30494,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 35661,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0080",
            "sentence": "Following primary vaccination, SAEs were reported for 4 infants in the 4DV group and 9 in the 1DV group (for 3 of them SAEs occurred between primary and booster), none being considered as vaccination-related.",
            "startOffset": 35453,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 35165,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0080",
            "sentence": "During the 31-day post-vaccination period, at least 1 unsolicited AE was reported after 2.1% of doses in the 4DV group and 3.7% of doses in the 1DV group; grade 3 unsolicited AEs were reported after 0.6% and 1.5% of doses, respectively.",
            "startOffset": 34929,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 40194,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 40193,
                    "startOffset": 40186
                },
                "b0120": {
                    "endOffset": 40193,
                    "startOffset": 40186
                }
            },
            "secId": "s0090",
            "sentence": "This is in line with the findings observed with the 4-dose presentation of PCV13 containing preservative [16,24].",
            "startOffset": 40081,
            "title": "Discussion"
        },
        {
            "endOffset": 35808,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0080",
            "sentence": "Two SAEs were fatal, 1 in the 4DV group (sepsis) and 1 in the 1DV group (septic shock), but their microbiological etiology could not be confirmed.",
            "startOffset": 35662,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 22791,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 22734,
                    "startOffset": 22730
                }
            },
            "secId": "s0005",
            "sentence": "PHiD-CV, as preservative-free 1-dose or 2-dose vial presentations [13], is prequalified by the World Health Organization (WHO).",
            "startOffset": 22664,
            "title": "Introduction"
        },
        {
            "endOffset": 27888,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 27887,
                    "startOffset": 27883
                }
            },
            "secId": "s0030",
            "sentence": "The assay cut-off was an opsonic titer of 8 as previously described [21].",
            "startOffset": 27815,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 28881,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "Fever was defined as axillary temperature \u226537.5 \u00b0C.",
            "startOffset": 28830,
            "title": "Reactogenicity and safety assessment"
        },
        {
            "endOffset": 30777,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Statistical Analysis System was used to perform statistical analyses.",
            "startOffset": 30708,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 36265,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0085",
            "sentence": "Solicited general AEs considered as vaccination-related were reported after less than 7.2% (irritability) of doses in the 4DV group, and after less than 3.4% (irritability) of doses in the 1DV group.",
            "startOffset": 36066,
            "title": "Booster vaccination phase"
        },
        {
            "endOffset": 32675,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0065",
            "sentence": "For each serotype, OPA GMTs were within the same ranges in both groups (Table 3).",
            "startOffset": 32594,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 24790,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Details regarding blinding and randomization are shown in supplementary text S2.",
            "startOffset": 24710,
            "title": "Study design and population"
        },
        {
            "endOffset": 33763,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0070",
            "sentence": "For serotypes 6A and 19A, at least 71.8% and 86.8% of infants in both groups, respectively, had OPA titers \u22658.",
            "startOffset": 33653,
            "title": "Booster vaccination phase"
        },
        {
            "endOffset": 24020,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "This phase III, single-center, observer-blind, controlled study (ClinicalTrials.gov: NCT02447432) was conducted in Bangladesh between June 2015 and May 2016.",
            "startOffset": 23863,
            "title": "Study design and population"
        },
        {
            "endOffset": 32081,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0065",
            "sentence": "One month post-primary vaccination, non-inferiority of PHiD-CV 4-dose versus 1-dose vial was demonstrated for each VT and vaccine-related serotype 19A (Fig. 2).",
            "startOffset": 31921,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 32860,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0065",
            "sentence": "Antibody GMCs were within similar ranges between the 4DV and 1DV groups (Table S2).",
            "startOffset": 32777,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 36457,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0085",
            "sentence": "During the 31-days post-booster dose, no unsolicited AEs were reported.",
            "startOffset": 36386,
            "title": "Booster vaccination phase"
        },
        {
            "endOffset": 43876,
            "parents": [],
            "secId": "s0105",
            "sentence": "DB, JRG, MAH and MT are employed by the GSK group of companies; DB, MAH and JRG hold shares of the GSK group of companies.",
            "startOffset": 43754,
            "title": "Disclosures"
        },
        {
            "endOffset": 25116,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Signed/thumb-printed and witnessed informed consent was obtained from the parent(s) or legally acceptable representative(s) (LAR[s]) of each infant before enrolment.",
            "startOffset": 24951,
            "title": "Study design and population"
        },
        {
            "endOffset": 26396,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "The confirmatory objectives were to demonstrate non-inferiority of the investigational PHiD-CV 4-dose vial versus licensed PHiD-CV 1-dose vial in terms of antibody geometric mean concentrations (GMCs) for each VT (primary objective) and vaccine-related serotype 19A (secondary objective) at 1 month post-primary vaccination.",
            "startOffset": 26072,
            "title": "Objectives"
        },
        {
            "endOffset": 40080,
            "parents": [],
            "secId": "s0090",
            "sentence": "Overall, these data suggest that the preservative included in the PHiD-CV 4-dose vial does not interfere with either the immune response to or the reactogenicity profile of PHiD-CV.",
            "startOffset": 39899,
            "title": "Discussion"
        },
        {
            "endOffset": 28487,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "Unsolicited AEs were reported within 31 days post-vaccination, and serious AEs (SAEs) throughout the study.",
            "startOffset": 28380,
            "title": "Reactogenicity and safety assessment"
        },
        {
            "endOffset": 36930,
            "parents": [],
            "secId": "s0090",
            "sentence": "While PHiD-CV is currently licensed as a pre-filled syringe, a 1-dose or a 2-dose vial, all preservative-free, this is the first study that evaluated a 4-dose vial presentation of PHiD-CV containing preservative.",
            "startOffset": 36718,
            "title": "Discussion"
        },
        {
            "endOffset": 26687,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "Additional secondary objectives were to assess immune responses of PHiD-CV 4-dose vial against VT and vaccine-related serotypes 6A and 19A at 1 and 5 months post-primary vaccination and 1 month post-booster vaccination, and against protein D at 1 month post-primary and booster vaccinations.",
            "startOffset": 26396,
            "title": "Objectives"
        },
        {
            "endOffset": 34929,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0080",
            "sentence": "No vaccination-related grade 3 fever was reported.",
            "startOffset": 34879,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 28078,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "Antibodies against the protein D carrier were measured at 1 month post-primary and 1 month post-booster vaccination in the same selected subset as OPA using an in-house ELISA (GSK, Belgium).",
            "startOffset": 27888,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 24614,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Eligibility criteria for inclusion in the study, and reasons for exclusion of infants from the study are presented in supplementary text S1.",
            "startOffset": 24474,
            "title": "Study design and population"
        },
        {
            "endOffset": 31148,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Of 160 vaccinated infants in each group, 154 and 146 infants in the 4DV and 1DV groups, respectively, were included in the ATP cohort for immunogenicity for primary vaccination (Fig. 1).",
            "startOffset": 30962,
            "title": "Study population"
        },
        {
            "endOffset": 42605,
            "parents": [],
            "secId": "s0090",
            "sentence": "The assessment of the functional OPA responses and immune responses to booster vaccination were descriptive and comparisons should be interpreted with caution due to multiple comparisons without adjustment for multiplicity.",
            "startOffset": 42382,
            "title": "Discussion"
        },
        {
            "endOffset": 43144,
            "parents": [],
            "secId": "s0095",
            "sentence": "PHiD-CV 4-dose vial also showed an acceptable reactogenicity profile.",
            "startOffset": 43075,
            "title": "Conclusion"
        },
        {
            "endOffset": 30961,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Informed consent was obtained from 213 literate and 107 illiterate (83 by signing, 24 by thumb impression) parents/LARs.",
            "startOffset": 30841,
            "title": "Study population"
        },
        {
            "endOffset": 25884,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0090": {
                    "endOffset": 25883,
                    "startOffset": 25879
                }
            },
            "secId": "s0020",
            "sentence": "Composition of the (co)-administered DTPw-HBV/Hib vaccine (Tritanrix HB and Hiberix, GSK) was previously published [18].",
            "startOffset": 25764,
            "title": "Study vaccines"
        },
        {
            "endOffset": 28127,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The assay cut-off was 153 ELISA units (EL.U)/mL.",
            "startOffset": 28079,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 29422,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "A total of 320 infants were planned to be enrolled, considering that up to 12.5% could be eliminated from the according-to-protocol (ATP) cohort for immunogenicity.",
            "startOffset": 29258,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 30840,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "In total, 320 infants were enrolled.",
            "startOffset": 30804,
            "title": "Study population"
        },
        {
            "endOffset": 33652,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0070",
            "sentence": "One month post-booster, at least 90.5% of infants had OPA titers \u22658 for each VT.",
            "startOffset": 33572,
            "title": "Booster vaccination phase"
        },
        {
            "endOffset": 38728,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 38727,
                    "startOffset": 38723
                }
            },
            "secId": "s0090",
            "sentence": "In addition, this study also assessed immunogenicity of the PHiD-CV 4-dose in terms of percentage of infants with antibody concentrations \u22650.2 \u00b5g/mL, percentage of infants with OPA titers \u22658 and OPA GMTs 1 month post-primary vaccination, following WHO recommendations [22].",
            "startOffset": 38455,
            "title": "Discussion"
        },
        {
            "endOffset": 40558,
            "parents": [],
            "secId": "s0090",
            "sentence": "At study end, we have recorded a maximum time after opening and until use of the last vial-dose of 23 days, which is close to the WHO allowed maximum after opening.",
            "startOffset": 40394,
            "title": "Discussion"
        },
        {
            "endOffset": 43443,
            "parents": [],
            "secId": "s0100",
            "sentence": "GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the study conduct and analysis.",
            "startOffset": 43324,
            "title": "Funding"
        },
        {
            "endOffset": 36066,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0085",
            "sentence": "No large swelling reactions were reported.",
            "startOffset": 36024,
            "title": "Booster vaccination phase"
        },
        {
            "endOffset": 37834,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 37833,
                    "startOffset": 37829
                }
            },
            "secId": "s0090",
            "sentence": "The 2-fold non-inferiority margin for the antibody GMC ratio was chosen because different PHiD-CV lots were previously shown to be within a 2-fold range [23].",
            "startOffset": 37676,
            "title": "Discussion"
        },
        {
            "endOffset": 30025,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "The percentages of infants reaching pre-defined immunologic cut-offs, antibody GMCs and OPA geometric mean titers (GMTs) were calculated with 95% confidence intervals (CIs).",
            "startOffset": 29852,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 39564,
            "parents": [],
            "secId": "s0090",
            "sentence": "No safety concerns were raised.",
            "startOffset": 39533,
            "title": "Discussion"
        },
        {
            "endOffset": 29627,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "A resulting 140 evaluable infants per group would provide at least 90.8% power (under equal mean) to show non-inferiority of PHiD-CV 4-dose vial versus PHiD-CV 1-dose vial in terms of antibody GMC ratios.",
            "startOffset": 29423,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 40393,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 40298,
                    "startOffset": 40294
                }
            },
            "secId": "s0090",
            "sentence": "In addition, as outlined in the WHO multi-dose vial policy and as required for WHO prequalification [14], the time limit for keeping the opened 4-dose vial with preservative was 28 days per protocol.",
            "startOffset": 40194,
            "title": "Discussion"
        },
        {
            "endOffset": 41688,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 41687,
                    "startOffset": 41683
                }
            },
            "secId": "s0090",
            "sentence": "PHiD-CV is administered in Bangladesh per local EPI schedule for pneumococcal vaccination at 6\u201310\u201318 weeks [32].",
            "startOffset": 41576,
            "title": "Discussion"
        },
        {
            "endOffset": 22918,
            "parents": [],
            "secId": "s0005",
            "sentence": "The previously licensed 2-dose vial improves logistics (delivery, storage and cold chain capacity) compared to the 1-dose vial.",
            "startOffset": 22791,
            "title": "Introduction"
        },
        {
            "endOffset": 24474,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Children received diphtheria-tetanus-whole cell pertussis-hepatitis B and H. influenzae type b conjugate vaccine (DTPw-HBV/Hib, GSK) and polio, measles and rubella vaccines as described in Fig. S1.",
            "startOffset": 24277,
            "title": "Study design and population"
        },
        {
            "endOffset": 32593,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0065",
            "sentence": "The percentage of infants with OPA titers \u22658 was at least 83.8% for each VT, and at least 54.5% and 80.6% for vaccine-related serotypes 6A and 19A.",
            "startOffset": 32446,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 29258,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Except for the confirmatory objectives related to immunologic non-inferiority, the other study objectives were descriptive.",
            "startOffset": 29135,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 29112,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "Causality of all other AEs was assessed by the investigators.",
            "startOffset": 29051,
            "title": "Reactogenicity and safety assessment"
        },
        {
            "endOffset": 34643,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0075",
                    "title": "Reactogenicity and safety results"
                }
            ],
            "secId": "s0080",
            "sentence": "Solicited general AEs considered by the investigator as vaccination-related were reported after less than 23.3% (irritability) of doses in the 4DV group, and after less than 26.6% (irritability) of doses in the 1DV group.",
            "startOffset": 34422,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 28960,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "AE intensity grades and SAE definitions are detailed in supplementary text S3.",
            "startOffset": 28882,
            "title": "Reactogenicity and safety assessment"
        },
        {
            "endOffset": 32446,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0065",
            "sentence": "Serotype-specific antibody GMCs were within similar ranges between groups (Table 2).",
            "startOffset": 32362,
            "title": "Primary vaccination phase"
        },
        {
            "endOffset": 31670,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Each vial dose from the PHiD-CV 4-dose presentation was evenly repartitioned between consecutive vaccinations (Table S1).",
            "startOffset": 31549,
            "title": "Use of the PHiD-CV 4-dose vial"
        }
    ],
    "docId": "S0264410X17317875",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "kzaman@icddrb.org",
                "first": "Khalequ",
                "initial": "K.",
                "last": "Zaman"
            },
            {
                "email": "sfzaman@icddrb.org",
                "first": "Sheikh Farzana",
                "initial": "S.F.",
                "last": "Zaman"
            },
            {
                "email": "drlisa83@yahoo.co.in",
                "first": "Farzana",
                "initial": "F.",
                "last": "Zaman"
            },
            {
                "email": "asma.aziz@icddrb.org",
                "first": "Asma",
                "initial": "A.",
                "last": "Aziz"
            },
            {
                "email": "sayeed.faisal@icddrb.org",
                "first": "Sayeed Bin",
                "initial": "S.B.",
                "last": "Faisal"
            },
            {
                "email": "magali.x.traskine@gsk.com",
                "first": "Magali",
                "initial": "M.",
                "last": "Traskine"
            },
            {
                "email": "Ahsan.M.Habib@gsk.com",
                "first": "Md Ahsan",
                "initial": "M.A.",
                "last": "Habib"
            },
            {
                "email": "javier.x.ruiz@gsk.com",
                "first": "Javier",
                "initial": "J.",
                "last": "Ruiz-Gui\u00f1az\u00fa"
            },
            {
                "email": "Dorota.D.Borys@gsk.com",
                "first": "Dorota",
                "initial": "D.",
                "last": "Borys"
            }
        ],
        "doi": "10.1016/j.vaccine.2017.12.034",
        "firstpage": "698",
        "issn": "0264410X",
        "keywords": [
            "1-dose vial presentation",
            "4-dose vial presentation",
            "Immunologic non-inferiority",
            "Infants",
            "Pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV)",
            "Safety"
        ],
        "lastpage": "706",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study"
    }
}